Latest Biomarkers News

Artrya Limited has completed the second tranche of its share placement, raising $14.7 million to advance its AI-powered Salix platform for coronary artery disease detection.

Alterity Therapeutics reports strengthened efficacy signals for ATH434 in Multiple System Atrophy and secures a robust cash position to fuel upcoming Phase 3 trials.

Cleo Diagnostics has successfully completed Stage 1 of the Medical Device Single Audit Program, marking a significant step toward FDA submission and global commercialisation of its ovarian cancer test.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

CONNEQT Health has landed a significant Phase 2b clinical trial contract in the US, advancing its footprint in cardiovascular disease research with proprietary vascular assessment technology.

Actinogen Medical has fast-tracked enrolment in its pivotal Alzheimer’s trial, secured a clear FDA regulatory path, and strengthened its financial position with funding extending its runway to mid-2026.

BlinkLab Limited has completed its U.S. pilot study for the Dx 1 smartphone-based autism diagnostic device, demonstrating strong accuracy and securing FDA alignment for its pivotal trial. The results mark a significant step toward transforming early neurodevelopmental diagnostics.

Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.

Actinogen Medical has fast-tracked recruitment in its XanaMIA Alzheimer’s trial, closing pTau biomarker screening early and increasing participant numbers, aiming for final results by mid Q4 2026.

Immutep’s novel immunotherapy combination with KEYTRUDA and chemotherapy shows promising response rates in first line non-small cell lung cancer, especially in patients with low or no PD-L1 expression.

Proteomics International has expanded its partnership with the University of Melbourne and Royal Women’s Hospital to further validate and develop its PromarkerEndo blood test, aiming to revolutionize endometriosis diagnosis.